新华制药(000756) - 2021 Q4 - 年度财报

Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching RMB 1.2 billion in 2021[14]. - The company's operating revenue for 2021 was RMB 6,560,077,586.40, representing a 9.23% increase compared to RMB 6,005,586,643.46 in 2020[16]. - The net profit attributable to shareholders of the listed company for 2021 was RMB 348,548,495.99, an increase of 7.29% from RMB 324,859,557.55 in 2020[16]. - The basic earnings per share for 2021 was RMB 0.56, up from RMB 0.52 in 2020, reflecting a 7.69% increase[16]. - The total revenue for 2021 reached ¥6,560,077,586.40, representing a 9.23% increase from ¥6,005,586,643.46 in 2020[155]. - The company achieved export revenue of USD 325,017 thousand in 2021, indicating exposure to foreign exchange risk[192]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[14]. - Future guidance indicates a projected revenue growth of 20% for 2022, aiming for RMB 1.44 billion[14]. - The company is actively pursuing market expansion strategies, as indicated by the involvement of independent directors with diverse industry backgrounds[40]. - The company plans to strengthen its market position amid challenges such as rising costs and intensified competition in the pharmaceutical sector[147]. - The company is focusing on talent acquisition, hiring 163 new employees, including 66 with master's degrees or higher[146]. Research and Development - The company has invested RMB 50 million in R&D for new drug development, focusing on oncology and chronic diseases[14]. - R&D expenses for the year totaled RMB 340 million, with 12 drug approvals and 14 patents granted[143]. - The company completed the construction of the injection drug R&D platform and GMP renovation project[144]. - The company is focused on enhancing its innovation capabilities through partnerships with research institutions and the establishment of a gene and cell engineering research center[150]. - R&D investment increased by 12.61% to RMB 328,029,328.76 from RMB 291,288,719.68 in 2020, representing 5.00% of operating revenue[175]. Corporate Governance - The company has established a strong governance framework with independent directors overseeing key operations, ensuring compliance and strategic direction[40]. - The company maintains a complete separation from its controlling shareholder in terms of business operations, assets, personnel, and financial management[71]. - The company has strengthened its corporate governance and compliance with relevant laws and regulations during the reporting period[73][74]. - The board of directors confirmed compliance with corporate governance codes during the fiscal year ending December 31, 2021[87]. - The company has appointed three independent non-executive directors, one of whom possesses financial management expertise[89]. Financial Health and Liabilities - The net cash flow from operating activities decreased by 38.33% to RMB 259,116,960.17 in 2021, down from RMB 420,186,808.35 in 2020[16]. - The company's total liabilities decreased by 0.56% to RMB 3,680,888,823.85 in 2021, compared to RMB 3,701,662,448.12 in 2020[16]. - The debt-to-asset ratio of the company is 50.20%[191]. - The company's liquidity ratios are stable, with a current ratio of 110.08% and a quick ratio of 69.00%[187]. - The company's total liabilities decreased by 44.17% in financing activities cash inflow to RMB 612,183,982.00 from RMB 1,096,573,800.00 in 2020[177]. Shareholder Information - The largest shareholder, China Hualu Holdings Group Co., Ltd., holds 32.65% of the shares, totaling 204,864,092 shares[26]. - The company has no pledged or frozen shares among its top shareholders[29]. - Shareholders holding more than 10% of voting shares can request a special general meeting, and if the board does not respond within 30 days, they may convene the meeting themselves[117]. - The company has established a contact point for shareholders to submit written inquiries or requests[119]. - The company has committed to covering reasonable expenses incurred by shareholders who convene a meeting due to the board's inaction[117]. Employee and Management Information - The company had a total of 6,533 employees as of December 31, 2021, with a total payroll of RMB 602.446 million for the year[58]. - The total annual remuneration for directors, supervisors, and senior management in 2021 amounted to RMB 13.4287 million[54]. - The company has established a training system that enhances employee capabilities and ensures effective management operations[61]. - The company's directors and senior management hold a total of 821,270 shares, with no holdings reported for supervisors[50]. - The company’s current board and senior management's term ends on December 22, 2023, indicating a stable leadership structure[48]. Audit and Compliance - The audit committee confirmed that the 2021 financial statements were prepared in accordance with the relevant accounting standards and accurately reflected the company's financial position[67][69]. - The audit committee recommended the reappointment of the auditing firm for the 2022 financial year[70]. - The independent directors attended all 11 board meetings and 4 audit committee meetings, with no absences reported[65][66]. - The company has established effective internal controls in all significant aspects, achieving its internal control objectives without any major deficiencies[81]. - The internal control audit report issued by the accounting firm confirmed that the company maintained effective financial reporting internal controls as of December 31, 2021[84].